Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Cipla

Drug and asset intelligence for Cipla with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 11
Catalysts: 0
Stage: Development stage unavailable

Recent signals(11)

CompetitiveAugust 1, 2026

Cipla's ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate Receives AP Status

Cipla's application ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 31, 2026

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Cipla's application ANDA210435 for Lenalidomide has received an abbreviated approval status from the FDA.

RegulatoryJuly 30, 2026

Cipla's Lenalidomide ANDA214618 Receives FDA AP Status

Cipla's ANDA214618 for Lenalidomide has received FDA approval status (AP) for its supplemental application.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Therapeutic areas

Anticoagulant →

Bronchodilator →

Cardiovascular →

Multiple Myeloma →

Respiratory →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

StrategyJuly 30, 2026

Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

Cipla's application for lenalidomide has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 28, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives FDA Approval Status

Cipla's application for Albuterol Sulfate (ANDA219409) has received an approval status of AP from the FDA.

StrategyJuly 7, 2026

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Cipla has received an abbreviated approval (AP) for its ANDA210435 application for Lenalidomide.

StrategyJuly 6, 2026

Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

Cipla's Abbreviated New Drug Application (ANDA) for Lenalidomide has received an Approval Pending (AP) status from the FDA.

RegulatoryJuly 5, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives AP Status from FDA

Cipla's application for Albuterol Sulfate has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJune 21, 2026

Cipla's NDA for Argatroban in Sodium Chloride Receives AP Status from FDA

Cipla's supplemental NDA for Argatroban in Sodium Chloride has been granted an Approval Pending (AP) status by the FDA.

StrategyJune 20, 2026

FDA Approves Albuterol Sulfate ANDA219409 from Cipla

The FDA has approved ANDA219409 for Albuterol Sulfate submitted by Cipla.

StrategyJune 18, 2026

Cipla's ANDA214209 for Sumatriptan Receives Abbreviated Approval from FDA

Cipla has received Abbreviated Approval (AP) from the FDA for its ANDA214209 application for Sumatriptan.